创作:花开 审核:szx 2018年09月22日
  • 纳入19项临床试验,评估ω-3多不饱和脂肪酸(PUFA)的抗焦虑作用;
  • 1203例受试者接受ω-3 PUFA治疗,1037例未接受ω-3 PUFA治疗,接受ω-3 PUFA治疗与焦虑症状改善相关,但仅高剂量(每天至少2000mg)组有明显作用;
  • 亚组分析提示,诊断出特定临床症状的受试者,焦虑症状的改善优于未发病受试者;
  • ω-3 PUFA可能有助于减轻焦虑的临床症状,但由于入选受试者的异质性、试验数偏少及样本量偏小等缺陷,结果的解读需谨慎。
JAMA [IF:45.54]

Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms A Systematic Review and Meta-analysis



2018-09-14, Review

Abstract & Authors:展开

Importance: No systematic review or meta-analysis has assessed the efficacy of omega-3 polyunsaturated fatty acids (PUFAs) for anxiety.
Objective : To evaluate the association of anxiety symptoms with omega-3 PUFA treatment compared with controls in varied populations.
Data Sources: PubMed, Embase, ProQuest, ScienceDirect, Cochrane Library, ClinicalKey, Web of Science, and ClinicalTrials.gov databases were searched up to March 4, 2018.
Study Selection: A search was performed of clinical trials assessing the anxiolytic effect of omega-3 PUFAs in humans, in either placebo-controlled or non–placebo-controlled designs. Of 104 selected articles, 19 entered the final data extraction stage.
Data Extraction and Measures: Two authors independently extracted the data according to a predetermined list of interests. A random-effects model meta-analysis was performed and this study was conducted based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.
Main Outcomes and Measures: Changes in the severity of anxiety symptoms after omega-3 PUFA treatment.
Results : In total, 1203 participants with omega-3 PUFA treatment (mean age, 43.7 years; mean female proportion, 55.0%; mean omega-3 PUFA dosage, 1605.7 mg/d) and 1037 participants without omega-3 PUFA treatment (mean age, 40.6 years; mean female proportion, 55.0%) showed an association between clinical anxiety symptoms among participants with omega-3 PUFA treatment compared with control arms (Hedges g, 0.374; 95% CI, 0.081-0.666; P = .01). Subgroup analysis showed that the association of treatment with reduced anxiety symptoms was significantly greater in subgroups with specific clinical diagnoses than in subgroups without clinical conditions. The anxiolytic effect of omega-3 PUFAs was significantly better than that of controls only in subgroups with a higher dosage (at least 2000 mg/d) and not in subgroups with a lower dosage (<2000 mg/d).
Conclusions and Relevance: This review indicates that omega-3 PUFAs might help to reduce the symptoms of clinical anxiety. Further well-designed studies are needed in populations in whom anxiety is the main symptom.

First Authors:
Kuan-Pin Su

Correspondence Authors:
Kuan-Pin Su,Yutaka J Matsuoka

All Authors:
Kuan-Pin Su,Ping-Tao Tseng,Pao-Yen Lin,Ryo Okubo,Tien-Yu Chen,Yen-Wen Chen,Yutaka J Matsuoka